By Inside Your Peptides · Originally published · Language revised 2026-09-17
Peptides do not share one evidence or approval status. Evaluate the specific molecule, product, route, population and outcome; keep trial findings, regulatory decisions and laboratory documentation separate.
Start with one precise claim
Peptide is a broad chemical description, not an evidence grade. For any claim, identify the molecule, product, route, population and measured outcome. Do not transfer an approved product's evidence to an unrelated research material or to a different use.
Use three separate evidence fields
Record study type and evidence strength, the direction of the measured outcome, and regulatory status in a named jurisdiction. No data is not the same as a negative trial. A biological mechanism is not a clinical result. Registration is not approval.
Read this year's updates critically
Registered BPC-157 studies and Lilly's retatrutide announcement show why status summaries need dates and exact sources. Neither resolves every clinical question. The legacy A-E table is withheld pending endpoint-specific review rather than presented as a verified ranking.
Sources used in this revision
- ClinicalTrials.gov · Rotator-cuff study NCT07803250 · Checked 17 September 2026
- ClinicalTrials.gov · Hamstring study NCT07437547 · Checked 17 September 2026
- Lilly · TRIUMPH-1 sponsor announcement, 21 May 2026 · Checked 17 September 2026
- FDA · Drug registration and listing · Checked 17 September 2026
Educational reading only. This page does not provide medical, dosing or personal-use guidance.